4 terminated, 2 withdrawn, 1 active not recruiting, 1 completed. 5 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow ME-401: new trials by email Literature Review of ME-401 trials Research Report on ME-401
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zandelisib + Tazemetostat in R/R Follicular Lymphoma TAZEMETOSTAT, Zandelisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 1 / Phase 2 | Withdrawn | Jacob Soumerai, MD | 2023-01-01 | 2023-07-07 | |
| Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Zandelisib, Rituximab, Venetoclax - CLL | Phase 2 | Withdrawn | MEI Pharma, Inc. | 2022-11-22 | 2023-03-16 | |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Deepa Jagadeesh | 13 | 2021-04-28 | 2025-02-07 |
| Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) ME-401 - Indolent B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Kyowa Kirin Co., Ltd. | 61 | 2020-09-17 | 2026-10-05 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Zandelisib (ME-401) - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 2 | Terminated | MEI Pharma, Inc. | 169 | 2019-06-25 | 2024-12-31 |
| Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma ME-401 - Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 14 | 2019-04-29 | 2025-12-19 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma ME-401, Rituximab, Zanubrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Terminated | MEI Pharma, Inc. | 97 | 2016-10-01 | 2023-05-09 |
Lymphoma, Follicular (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
MEI Pharma, Inc. (4) · Kyowa Kirin Co., Ltd. (2) · Deepa Jagadeesh (1) · Jacob Soumerai, MD (1)
United States (5) · Japan (3) · Australia (2) · Belgium (2) · France (2) · Italy (2) · New Zealand (2) · Poland (2) · South Korea (2) · Spain (2) · Switzerland (2) · Taiwan (2) · United Kingdom (2) · Austria (1) · Canada (1)
Deepa Jagadeesh, MD, MPH (1) · Jacob D. Soumerai, MD (1)
PMID 35835137, PMID 36107394, PMID 39778876
2018 (1)